We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.14% | 44.05 | 950 | 11:12:13 |
From May 2019 to May 2024
By Adriano Marchese
Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma.
The New York-based pharmaceutical company said the approval follows a Phase 3 trial result that showed the drug nivolumab, also known as Opdivo, in combination with Cabometyx--cabozantinib--significantly improved overall survival objective response rates compared to sunitinib--another cancer-treatment drug.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 14, 2021 16:43 ET (20:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
